Prescription charges for antiviral medicines to treat COVID-19 will be waived until 31 March 2023, the DHSC has announced.
The waiver applies to the following patients:
- those who are eligible to receive antiviral treatments for COVID-19 via COVID Medicines Delivery Units (CMDUs)
- STIMULATE ICP treating community patients for long COVID
- therapeutic treatments available through the National Institute for Health Research (NIHR) funded HEAL-COVID clinical trial platform treating patients who have been hospitalised for COVID-19.